Pacira Biosciences Inc 's Cash & cash equivalent grew by 17.75 % in the Q3 2026 sequentially, faster than Current Liabilities, this led to improvement in Pacira Biosciences Inc 's Quick Ratio to 2.31, Quick Ratio remained below Pacira Biosciences inc average.

Within Major Pharmaceutical Preparations industry 289 other companies have achieved higher Quick Ratio than Pacira Biosciences Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 1141 to 1386.

Explain Quick Ratio?
How much Cash & cash equivalents PCRX�s has?
What are PCRX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/PCRX/financial-strength

https://api.csimarket.com/api/v1/companies/PCRX/fundamentals

https://api.csimarket.com/api/v1/companies/PCRX/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

PCRX Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	19.73 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	19.99 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	2.31	Subscribe	Subscribe	Subscribe	Subscribe
PCRX's Total Ranking	# 1386	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	5.08 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	17.75 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 290
Healthcare Sector	# 501
Overall Market	# 1386

Quick Ratio Statistics
High	Average	Low
21.12	3.72	0.54
(Dec 31 2016)		(Mar 31 2014)

Financial Statements
Pacira Biosciences Inc 's Current Liabilities	$ 128 Millions	Visit PCRX's Balance sheet
Pacira Biosciences Inc 's Cash & cash equivalent	$ 296 Millions	Visit PCRX's Balance sheet
Source of PCRX's Sales		Visit PCRX's Sales by Geography

Cumulative Pacira Biosciences Inc 's Quick Ratio

PCRX's Quick Ratio for the trailling 12 Months

PCRX Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-53.51 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-40.9 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	2.03	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3891	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	4.55 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	5.25 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to PCRX Financial Strength Comparisons >> Go to Compare PCRX Quick Ratio to its Competitors

On the trailing twelve months basis PCRX Cash & cash equivalent increased by 19.99 % in Q3 2026 year on year, faster than Current Liabilities, this led to increase in in Pacira Biosciences Inc 's Quick Ratio to 2.03, Quick Ratio remained below PCRX average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 430 other companies have achieved higher Quick Ratio than Pacira Biosciences Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2923 to 3891.

Explain Quick Ratio?
How much Cash & cash equivalents PCRX�s has?
What are PCRX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 431
Healthcare Sector	# 885
Within the Market	# 3891

trailing twelve months Quick Ratio Statistics
High	Average	Low
6.84	2.78	0.79
(Mar 31 2019)		(Jun 30 2014)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Camp4 Therapeutics Corporation	6.27	$ 124.522 Millions	$ 19.865 Millions
Context Therapeutics Inc	6.26	$ 34.411 Millions	$ 5.501 Millions
Sagimet Biosciences inc	6.22	$ 236.397 Millions	$ 37.985 Millions
Bridgebio Oncology Therapeutics Inc	6.18	$ 315.331 Millions	$ 51.026 Millions
Reviva Pharmaceuticals Holdings Inc	6.14	$ 33.647 Millions	$ 5.478 Millions
Cartesian Therapeutics Inc	6.12	$ 122.975 Millions	$ 20.088 Millions
Olema Pharmaceuticals Inc	5.98	$ 413.771 Millions	$ 69.233 Millions
Summit Therapeutics Inc	5.71	$ 629.899 Millions	$ 110.226 Millions
Nurix Therapeutics Inc	5.51	$ 720.458 Millions	$ 130.742 Millions
United Therapeutics Corporation	5.51	$ 3,439.800 Millions	$ 624.300 Millions
Immuneering Corporation	5.45	$ 58.776 Millions	$ 10.791 Millions
Rocket Pharmaceuticals Inc	5.22	$ 279.470 Millions	$ 53.508 Millions
Aquestive Therapeutics Inc	5.22	$ 90.349 Millions	$ 17.299 Millions
Sionna Therapeutics Inc	5.11	$ 83.878 Millions	$ 16.420 Millions
Gain Therapeutics inc	4.94	$ 11.698 Millions	$ 2.369 Millions
Rani Therapeutics Holdings Inc	4.91	$ 45.288 Millions	$ 9.223 Millions
Abeona Therapeutics Inc	4.87	$ 134.941 Millions	$ 27.707 Millions
Hoth Therapeutics Inc	4.87	$ 6.016 Millions	$ 1.237 Millions
Shattuck Labs Inc	4.84	$ 61.758 Millions	$ 12.758 Millions
Mereo Biopharma Group Plc	4.75	$ 26.097 Millions	$ 5.494 Millions
Spruce Biosciences Inc	4.69	$ 87.691 Millions	$ 18.710 Millions
Diamedica Therapeutics Inc	4.68	$ 34.905 Millions	$ 7.454 Millions
Eledon Pharmaceuticals Inc	4.61	$ 69.672 Millions	$ 15.099 Millions
Septerna Inc	4.56	$ 478.601 Millions	$ 104.863 Millions
Atossa Therapeutics Inc	4.37	$ 20.574 Millions	$ 4.709 Millions
Adial Pharmaceuticals Inc	4.35	$ 22.000 Millions	$ 5.056 Millions
Neurogene Inc	4.35	$ 78.942 Millions	$ 18.163 Millions
Entrada Therapeutics Inc	4.34	$ 112.302 Millions	$ 25.863 Millions
Gyre Therapeutics Inc	4.34	$ 86.190 Millions	$ 19.874 Millions
Serina Therapeutics Inc	4.28	$ 19.403 Millions	$ 4.529 Millions

Date modified: 2026-11-07T13:19:36+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.